10-Q: Moleculin Biotech Faces Nasdaq Delisting Amidst Deep Losses

Moleculin Biotech reports significant net losses and negative stockholders' equity, raising substantial doubt about its ability to continue as a going concern, while advancing its lead drug Annamycin in Phase 3 trials.

Summary

• Moleculin Biotech, Inc. reported a net loss of $25.4 million for the three months ended September 30, 2025, a significant increase from $7.0 million in the same period of 2024.
• The net loss for the nine months ended September 30, 2025, was $49.1 million, compared to $19.5 million for the prior year period.
• The company's accumulated deficit reached $221.6 million as of September 30, 2025, and total stockholders' equity shifted to a deficit of $26.9 million from a positive $11.2 million at December 31, 2024.
• Cash and cash equivalents stood at $6.7 million as of September 30, 2025, which management believes is insufficient to fund operations for at least one year.
• The company requires approximately $7 million in additional funding to support operations into the second quarter of 2026.
• Moleculin is not in compliance with Nasdaq's minimum stockholders' equity rule ($2.5 million) and minimum bid price rule ($1.00 per share), facing potential delisting.
• The company is conducting a pivotal Phase 3 MIRACLE trial for Annamycin in relapsed/refractory Acute Myeloid Leukemia (AML), with 60% of the first 45 subjects consented as of November 4, 2025.
• Annamycin has shown no evidence of cardiotoxicity in 84 subjects across five clinical trials, even at doses significantly exceeding FDA lifetime maximums for other anthracyclines.
• Clinical data from the completed Phase 1B/2 MB-106 trial for AML showed a median overall survival (OS) of 15+ months for complete remissions (CR) and 12 months for the second-line safety evaluable population, compared to typical OS of 4-6 months for relapsed AML patients.
• The company changed its accounting policy for certain warrants from liability to equity classification, retrospectively applied, which significantly impacted financial statement line items.
• Significant warrant issuances and exercises occurred, leading to substantial dilution, with common stock outstanding increasing to 49.5 million shares at September 30, 2025, from 3.4 million at December 31, 2024.
• New patents for Annamycin formulation were granted in Australia, Canada, and Europe, and the WHO approved 'naxtarubicin' as the international non-proprietary name for Annamycin.

Sentiment

Score: 3

Explanation: While there is promising clinical progress for Annamycin, the company's severe financial distress, including substantial net losses, negative stockholders' equity, going concern doubt, and immediate Nasdaq delisting risks, overshadows the positive clinical developments. The significant dilution from recent capital raises and the need for further funding add to the precarious financial outlook.

Positives

• Annamycin, the lead drug candidate, continues to show no evidence of drug-related cardiotoxicity in 84 subjects across five clinical trials, even at doses significantly above FDA lifetime maximums.
• The completed Phase 1B/2 MB-106 trial for AML demonstrated promising median overall survival (OS) of 15+ months for complete remissions (CR) and 12 months for the second-line safety evaluable population, exceeding the typical 4-6 months for relapsed AML patients.
• The FDA has agreed to a single pediatric approval study for Annamycin in children with relapsed/refractory AML, expected to commence in the second half of 2027.
• Final top-line data from the MB-107 trial for Soft Tissue Sarcoma (STS) Lung Metastases showed a median OS of 13.5 months for subjects receiving 7th line therapy, comparable to or exceeding standard of care and experimental 2nd line treatments.
• New patents for Annamycin's preliposomal lyophilizate formulation were granted in Australia, Canada, and Europe, extending exclusivity until at least June 2040.
• The World Health Organization (WHO) approved 'naxtarubicin' as the International Non-Proprietary Name (INN) for Annamycin, establishing global recognition.
• The company successfully raised $19.8 million in net cash from financing activities during the nine months ended September 30, 2025, compared to $4.6 million in the prior year period.
• Research and development expenses decreased by $2.5 million for the nine months ended September 30, 2025, primarily due to lower drug production costs.

Negatives

• The company reported a substantial net loss of $49.1 million for the nine months ended September 30, 2025, significantly higher than $19.5 million in the prior year.
• Accumulated deficit increased to $221.6 million as of September 30, 2025, from $172.4 million at December 31, 2024.
• Total stockholders' equity shifted to a deficit of $26.9 million as of September 30, 2025, from a positive $11.2 million at December 31, 2024.
• Cash on hand of $6.7 million as of September 30, 2025, is not sufficient to fund planned operations for at least one year, raising substantial doubt about the company's ability to continue as a going concern.
• The company requires approximately $7 million in additional funding to continue operations into the second quarter of 2026.
• Moleculin is not in compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) and minimum bid price requirement ($1.00 per share), facing potential delisting from the Nasdaq Capital Market.
• The number of common shares outstanding increased dramatically to 49.5 million at September 30, 2025, from 3.4 million at December 31, 2024, indicating significant shareholder dilution.
• The Series E and Series F warrants contain 'Down Round Features' that could further reduce exercise prices and increase the number of shares issuable, leading to additional dilution if future equity is raised at lower prices.
• An ongoing SEC investigation, initiated in March 2022, regarding a COVID-19 drug candidate and related statements, creates regulatory uncertainty.
• The company recognized a significant loss on issuance of warrant liabilities of $31.0 million for the nine months ended September 30, 2025, due to the fair value of liability-classified warrants exceeding total proceeds.

Risks

• Inability to obtain additional funding to commence or continue clinical trials, fund operations, and develop product candidates, which is critical given the current cash position and accumulated deficit.
• Failure to regain and maintain compliance with Nasdaq's continued listing requirements, specifically the $2.5 million minimum stockholders' equity and the $1.00 minimum bid price, which could lead to delisting and negatively impact stock liquidity and value.
• The potential for significant dilution of existing stockholders' ownership interest due to the future exercise of outstanding warrants, especially those with 'Down Round Features' that can reduce exercise prices and increase the number of shares issuable.
• The ongoing SEC investigation, which could result in unpredictable actions by the SEC and potential adverse impacts on the company.
• Reliance on third-party manufacturers for drug products and third-party academic institutions for investigator-initiated clinical and preclinical studies.
• Risks associated with clinical trials, including the ability to recruit subjects, onboard sites, satisfy FDA requirements, and achieve successful outcomes.
• Potential for world-wide events, geopolitical conflicts, public health emergencies, and global supply chain disruptions to affect clinical trials and drug candidate supplies.
• Inability to obtain and retain regulatory approval for drug candidates in the US, Europe, and other countries.
• Competition from existing or new therapies in the oncology and antiviral markets.
• Potential product liability claims related to drug candidates.
• Inability to establish or maintain collaborations, licensing, or other arrangements for commercialization.
• Challenges in protecting intellectual property rights and adequately supporting future growth.

Future Outlook

The company anticipates continued progress in its pivotal Phase 3 MIRACLE trial for Annamycin, with unblinding of data for the first 45 subjects expected in the first quarter of 2026, followed by data for the first 90 subjects. A pediatric approval study for Annamycin in R/R AML is expected to commence in the second half of 2027. An investigator-initiated Phase 1B/2 study for Annamycin in advanced pancreatic cancer is planned to begin in 2026. The company intends to seek additional funding through various means, including equity offerings, debt financings, and strategic partnerships, to support its operations and clinical development beyond the first quarter of 2026. Management will continue to monitor its common stock bid price and may consider a reverse stock split to regain Nasdaq compliance.

Management Comments

• "We believe that such early visibility for a pivotal registration-enabling trial is highly unique in that stakeholders will receive preliminary safety and efficacy data in the MIRACLE trial within roughly one year of dosing the first subject."
• "We believe the Expert's reports are particularly relevant in light of a recently published retrospective study showing that the incidence of heart failure more than doubles for cancer patients treated with anthracyclines compared to cancer patients not receiving anthracyclines."
• "We believe that the potential for such future incidences, however, does not outweigh the significant lack of cardiotoxicity to date as reflected in the Experts reports."
• "We intend to monitor the closing bid price of our common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split."
• "We believe that our cash on hand and cash equivalents as of September 30, 2025, is sufficient to fund our planned operations into the first quarter of 2026."
• "We must seek additional funds of approximately $7 million, to support MIRACLE and our operations into the second quarter of 2026."

Industry Context

Moleculin Biotech operates in the highly competitive and capital-intensive clinical-stage pharmaceutical industry, focusing on oncology and antiviral therapies. Its lead drug, Annamycin, is an anthracycline, a class of chemotherapy known for cardiotoxicity. Moleculin's strategy to develop a non-cardiotoxic anthracycline could be disruptive, addressing a significant unmet need in cancer treatment, particularly for AML and STS where current therapies have limitations. The company's reliance on investigator-initiated studies for its other portfolios (WP1066, WP1122) is a common strategy for smaller biotechs to leverage external funding and expertise. The ongoing clinical trial progress, especially the Phase 3 MIRACLE trial, positions it among companies advancing late-stage oncology assets, but its precarious financial position and Nasdaq compliance issues highlight the inherent risks of this industry segment.

Comparison to Industry Standards

• Annamycin's lack of observed cardiotoxicity in 84 subjects, even at doses significantly above the FDA's lifetime maximum anthracycline limit of 550 mg/m2, stands in stark contrast to the known cardiotoxic effects of commonly prescribed anthracyclines, which can more than double the incidence of heart failure in cancer patients (C Larson, et al. JAMA Network Open. 2023).
• The median overall survival (OS) of 15+ months for complete remissions (CR) and 12 months for the 2nd line safety evaluable population in the MB-106 AML trial significantly surpasses the typical OS of 4-6 months for relapsed AML patients reported in industry publications.
• The MB-107 trial for STS Lung Metastases showed a median OS of 13.5 months for subjects receiving 7th line therapy, which compares favorably to OS of 8-12 months for standard of care treatments and 13.4 months for experimental treatments for advanced STS as 2nd line (Comandone A, et al; The Oncologist 2017;22:15181527), suggesting potential efficacy even in heavily pre-treated patients.

Management Changes

Corporate Governance

Legal Proceedings

• An ongoing subpoena from the SEC, received in March 2022, requesting information and documents related to certain individuals and entities, and materials related to the development of and statements regarding the company's drug candidate for the treatment of COVID-19. The company is not aware of the specific nature of the underlying investigation and cannot predict its resolution or any potential SEC actions.

Related Party Transactions

• The company recorded approximately $12,000 in sublease income from a related party for the three months ended September 30, 2025 and 2024, and $37,000 for each of the nine months ended September 30, 2025 and 2024.
• Expenses with Houston Pharmaceuticals, Inc. (HPI), a related party, were $15,000 for each of the three months ended September 30, 2025 and 2024, and $45,000 and $176,000 for the nine months ended September 30, 2025 and 2024, respectively.
• Accounts payable due to related party was $19,000 and $20,000 at September 30, 2025 and December 31, 2024, respectively.

Stakeholder Impact

• **Shareholders**: Significant dilution has occurred and is likely to continue due to warrant exercises and future capital raises. The negative stockholders' equity and Nasdaq delisting risk pose substantial threats to shareholder value and liquidity. The ongoing SEC investigation adds uncertainty.
• **Employees**: The company's going concern doubt and need for additional financing could create job insecurity, although stock-based compensation is a component of their remuneration.
• **Customers (future patients)**: Progress in clinical trials, particularly for Annamycin, offers potential new treatment options for hard-to-treat cancers like AML and STS, potentially improving patient outcomes, especially given the lack of cardiotoxicity.
• **Suppliers/Creditors**: The company's precarious financial position and going concern doubt could raise concerns for suppliers and creditors regarding payment reliability.
• **Regulatory Authorities**: The company is actively engaging with the FDA and EMA for clinical trial approvals and pediatric study plans, demonstrating adherence to regulatory processes, despite the ongoing SEC investigation.

Next Steps

• Unblinding and release of preliminary safety and efficacy data for the first 45 subjects in the MIRACLE trial in Q1 2026.
• Unblinding of data for the first 90 subjects in the MIRACLE trial, followed by Data Safety Monitoring Committee (DSMC) recommendations.
• Submission of results from appropriate nonclinical GLP studies before initiating Part B (Phase 3 portion) of the MIRACLE study in the EU.
• Publication of the final Clinical Study Report (CSR) for the MB-106 AML trial in Q1 2026.
• Commencement of an investigator-initiated Phase 1B/2 single-arm study for Annamycin in third-line advanced pancreatic cancer with Atlantic Health in 2026.
• Completion of in vitro studies for WP1066 IV formulations in Q4 2025 and in vivo studies in H1 2026 at Emory University.
• Publication of a manuscript covering the prior pediatric study for WP1066 treating brain tumors in H2 2026.
• Commencement of a single pediatric approval study for Annamycin in children with R/R AML in H2 2027.
• Monitoring of common stock bid price and potential consideration of a reverse stock split to regain Nasdaq compliance.
• Seeking additional funding of approximately $7 million to support operations into Q2 2026 through equity offerings, debt financings, or strategic arrangements.
• Continued response to periodic requests from the SEC staff regarding the ongoing investigation.

Key Dates

Recommendation

Moleculin Biotech faces severe financial distress, evidenced by a rapidly increasing accumulated deficit, negative stockholders' equity, and a stated going concern doubt. The company is not in compliance with multiple Nasdaq listing requirements, making delisting a high probability. While clinical data for Annamycin shows promise, the company's need for substantial additional capital, coupled with the highly dilutive nature of its recent financing activities and the 'Down Round Features' of its warrants, presents an extremely high risk of further capital erosion for investors. The ongoing SEC investigation adds another layer of uncertainty. For a seasoned investor, the significant financial risks and potential for substantial further dilution far outweigh the early-stage clinical positives, warranting a strong sell recommendation to preserve capital.

Keywords

Annamycin, naxtarubicin, AML, Acute Myeloid Leukemia, Relapsed/Refractory AML, Phase 3 Clinical Trial, Oncology, Cardiotoxicity, Nasdaq Compliance, Biotechnology, Pharmaceuticals, Warrants, Dilution, Going Concern, SEC Filing, Clinical Stage, Soft Tissue Sarcoma, Pancreatic Cancer, Glioblastoma